View More Recent Stories
-
Masimo Corp. (MASI) Tops Q2 EPS by 9c; updates guidance
-
Masimo (MASI): New Study Finds That Remote Patient Monitoring with Masimo SafetyNet Significantly Reduced Rates of Hospital Readmission and ED Visits
-
Politan Comments on Masimo’s (MASI) Latest Entrenchment Maneuvers
-
ISS Recommends Masimo (MASI) Shareholders Vote FOR Both of Politan’s Director Nominees
-
Masimo Corp. (MASI) Responds to Politan’s Continuing Misrepresentations
-
Stifel Reiterates Buy Rating on Masimo Corp. (MASI)
-
BTIG Reiterates Buy Rating on Masimo (MASI) following prelim Q2 report
-
Masimo (MASI) announces preliminary Q2 revenue above consensus estimates
-
Masimo Corp. (MASI) Announces Preliminary Second Quarter 2024 Revenue and Select Financial Results
-
Masimo Corp. (MASI): Update on Potential Separation of Consumer Business
-
Masimo Corp. (MASI) Issues Response to "Latest Politan Fictions"
-
Masimo Corp. (MASI) Issues Shareholder Letter
-
Masimo Corp. (MASI) Files Latest Presentation Highlighting Innovation-Driven Value, Strategic Initiatives
-
Piper Sandler Reiterates Overweight Rating on Masimo Corp. (MASI)
-
Masimo (MASI) Files Definitive Proxy, Issues Letter to Stockholders

